Abstract
Specific inhibitors of monoamine oxidase type B (MAO-B) constitute a novel and expanding pharmacological class. At present, only one compound from this class is marketed, selegiline (deprenyl). Other MAO-B inhibitors that are in various stages of development include lazabemide and mofegiline, which are differentiated from selegiline by their greater specificity for MAO-B and the absence of active metabolites.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
